Search
Search Results
##search.searchResults.foundPlural##
-
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3666PDF: 904HTML: 6722 -
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy
2819PDF: 775HTML: 1281Blood Count trend before and during lenalidomide treatment: 176Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 198 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1204PDF: 768HTML: 1376Figure 1: 195Figure 2: 197 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1639PDF: 520HTML: 164 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2246PDF: 823HTML: 1636Figure 1: 195Table 1: 217 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1389PDF: 857HTML: 139 -
DNA Repair Genes and Chronic Myeloid Leukemia: XPD (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (1394) Gene Polymorphisms Polymorphisms of DNA Repair Genes in CML
1113PDF: 444HTML: 252 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
830PDF: 426HTML: 301 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1875PDF: 729HTML: 2119Untitled: 225Untitled: 158Untitled: 177Untitled: 161Untitled: 169Untitled: 184Untitled: 191 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1278PDF: 773HTML: 321 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1421PDF: 1327HTML: 101 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2956PDF: 1601HTML: 239 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1048PDF: 493Suppl. Files: 125HTML: 124 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2201PDF: 978HTML: 2173 -
-
DONOR KIR3DL1/RECEPTOR HLA-BW4-80I COMBINATION REDUCES ACUTE LEUKEMIA RELAPSE AFTER UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION KIR3DL1 with HLA-Bw4-80I reduces leukemia relapse
1402PDF: 549HTML: 209 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2303PDF: 1647HTML: 276 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1569PDF: 801HTML: 216 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1071PDF: 1181Suppl. Files: 570HTML: 90 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2882PDF: 858HTML: 6533Untitled: 237Untitled: 200Untitled: 212Untitled: 225 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1270PDF: 1017HTML: 226 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2604PDF: 880HTML: 2125 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1728PDF: 823HTML: 176







